SEC Comment Letter 0000000000-24-005221 to AVENUE THERAPEUTICS, INC. (ATXI) (CIK 0001644963) (ATXI)
AVENUE THERAPEUTICS, INC. (ATXI) (CIK 0001644963)
Date: May 8, 2024 · CIK: 0001644963 · Accession: 0000000000-24-005221
AI Filing Summary & Sentiment
File numbers found in text: 333-279125
Letter
United States securities and exchange commission logo May 8, 2024 Alexandra MacLean, M.D. Chief Executive Officer Avenue Therapeutics, Inc. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, Florida 33154 Re:Avenue Therapeutics, Inc. Registration Statement on Form S-3 Filed May 6, 2024 File No. 333-279125 Dear Alexandra MacLean: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: David S. Wolpa
Show Raw Text
United States securities and exchange commission logo
May 8, 2024
Alexandra MacLean, M.D.
Chief Executive Officer
Avenue Therapeutics, Inc.
1111 Kane Concourse, Suite 301
Bay Harbor Islands, Florida 33154
Re:Avenue Therapeutics, Inc.
Registration Statement on Form S-3
Filed May 6, 2024
File No. 333-279125
Dear Alexandra MacLean:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: David S. Wolpa